8 results on '"Wesenberg F"'
Search Results
2. Central Nervous System Disease in Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Results of Treatment
- Author
-
Kreuger, A., primary, Garwicz, S., additional, Hertz, H., additional, Jonmundsson, C., additional, Latining, M., additional, Lie, S. O., additional, Moe, P. J., additional, Salmi, T. T., additional, Schröder, H., additional, Siimes, M. A., additional, Wesenberg, F., additional, Yssing, M., additional, Åhström, L., additional, and Gustafsson, G., additional
- Published
- 1991
- Full Text
- View/download PDF
3. Central Venous Catheter with Subcutaneous Injection Port (Port-A-Cath): Clinical Experience with Children
- Author
-
Wesenberg, F., Anker, C., Sommerschild, H., and Flaatten, H.
- Abstract
Long-term intermittent venous access was established in 26 children by means of a central venous catheter (CVC) with a subcutaneous injection port (Port-A-Cath) (PAC). As of December, 1985, PACs had been in place for 20-750 days (cumulative 10,890 days) with 647 entries into the system. The PACs were used for blood sampling and administration of chemotherapy, antibiotics, fluids, total parenteral nutrition (TPN), and blood products. One patient with severe neutropenia (absolute neutrophil granulocyte count [ANC] < 0.1 × 109/L) at the time of the PAC implant developed an infection around the port after 2 days, with subsequent septicemia (Bacillus cereus) necessitating removal of the PAC. Otherwise, no definite PAC-related infections occurred, including 258 days of neutropenia (ANC < 0.5 × 109/L). Two PACs were found occluded with greyish deposits of fat and organic material after long-term (45 and 61 days) continuous TPN and were removed. Malposition of catheter, extravasation, thrombosis, and other potential technical or psychological complications were not observed. The children continued normal activities, and the easy venous access decreased emotional stress during treatment. Local doctors were trained to use the PACs, with which they administered maintenance chemotherapy. We conclude that the use of PACs in children is safe, even in the first year of life, and has many advantages when compared with other CVCs currently in use. Strict indications, meticulous implantation technique, and adequate handling are, however, mandatory.
- Published
- 1987
- Full Text
- View/download PDF
4. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
- Author
-
Ruud E, Holmstrøm H, de Lange C, Natvig S, Albertsen BK, and Wesenberg F
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antithrombins analysis, Asparaginase administration & dosage, Catheterization, Central Venous adverse effects, Child, Child, Preschool, Erwinia enzymology, Escherichia coli enzymology, Female, Humans, Infant, Jugular Veins, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Protein C analysis, Protein S analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Asparaginase adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Thrombophilia chemically induced, Venous Thrombosis chemically induced
- Abstract
Asparaginase is essential in the treatment of lymphoproliferative malignancies, but it is associated with several side effects. The objective of this study was to compare asparaginase-induced alterations of the coagulation inhibitors and the impact on central line-associated thrombosis in children treated according to 2 different asparaginase regimens. The study enrolled 30 children treated for acute lymphoblastic leukemia, and they were divided into 2 groups with respect to asparaginase preparation and protocol (NOPHO ALL-1992 versus NOPHO ALL-2000). The coagulation inhibitors antithrombin, protein C, and proteins S were measured prior to and during asparaginase therapy, and incidence of central line-associated thromboses was compared to evaluate the protocols' thrombogenicity. Thirteen children received Erwinia asparaginase and 17 children received E. coli asparaginase. Independent of protocol, the coagulation inhibitors were significantly reduced during asparaginase therapy (p < .001), and central line-associated thromboses were frequent. Four children developed thrombosis in the course of asparaginase therapy, and there was a correlation between asparaginase-induced fall of antithrombin and occurrence of new thromboses (p = .01).
- Published
- 2006
- Full Text
- View/download PDF
5. Diagnostic value of family histories of thrombosis to identify children with thrombophilia.
- Author
-
Ruud E, Holmstrøm H, Brosstad F, and Wesenberg F
- Subjects
- Child, Child, Preschool, Female, Humans, Male, Predictive Value of Tests, Risk Factors, Thrombophilia genetics, Pedigree, Thromboembolism genetics, Thrombophilia diagnosis
- Abstract
Thrombophilia screening is a time-consuming and expensive procedure. Information about thromboembolism among relatives may be a simple method to identify those at risk of having thrombophilia. In a cross-sectional clinical study the authors have investigated the role of such family histories to detect children with thrombophilia. In 202 children a family history of venous or arterial thromboembolism was recorded. The participants were either children with congenital heart defects at the time of a scheduled cardiac catheterization (n=134) or children with newly diagnosed cancer (n=68). Questions were answered, on the spot, by the parents, at the same time as blood samples for thrombophilia screening were taken. Questions about family history of thromboembolism were completed in 184 children, of whom 114 children (62%) were positive, and 35 of these had relatives with venous thromboembolic events. Only one child had an affected first-degree relative. Thrombophilic alterations were observed in 60 children (30%), and 25 of these were defined as inherited. A positive family history of venous origin increased the relative risk of a child having inherited thrombophilia to 2.35 (95% confidence interval 1.1--5.2). Information about familial arterial thromboembolism was not useful in spotting children with prothrombotic risk factors. These results indicate that questioning about family history of venous thromboembolism may identify children with genetic thrombophilia, but the association is not strong. The authors encourage similar larger-scale studies to enlighten the issue fully.
- Published
- 2005
- Full Text
- View/download PDF
6. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration.
- Author
-
Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, and Wesenberg F
- Subjects
- Adolescent, Age Factors, Bone Marrow pathology, Child, Child, Preschool, Erythrocyte Transfusion, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Norway epidemiology, Platelet Count, Prospective Studies, Purpura, Thrombocytopenic, Idiopathic pathology, Purpura, Thrombocytopenic, Idiopathic therapy, Sex Factors, Purpura, Thrombocytopenic, Idiopathic epidemiology, Registries
- Abstract
A prospective, population-based registration of children with immune thrombocytopenic purpura (ITP) was performed in Norway in 1996 and 1997. Ninety-two cases were identified, indicating an incidence of 5.3 per 100,000 children under 15 years. The sex ratio (female/male) was 1.2/1. Fifty-six percent presented with cutaneous signs only. The lowest platelet count was < 20 x 10(9)/L in 91%. In spite of mild bleeding symptoms, medical treatment was given in 68%, in most cases (57/63) with intravenous immunoglobulin. A total of 41/44 patients with platelet counts of < or = 5 x 10(9)/L were treated, regardless of whether they had mucous bleedings or not. Eighteen percent had platelet counts < 150 x 10(9)/L at 6 months, and 9% at 12 months following diagnosis. One patient with therapy-resistant chronic ITP died 16 months after diagnosis from an anesthesia complication related to profound epistaxis. This study shows a relatively high incidence. As in other studies, there was a tendency to treat platelet counts rather than bleeding symptoms.
- Published
- 2000
- Full Text
- View/download PDF
7. Thyroid function in children after cytostatic treatment for acute leukemia.
- Author
-
Nygaard R, Bjerve KS, Kolmannskog S, Moe PJ, and Wesenberg F
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Male, Leukemia, Myeloid, Acute drug therapy, Methotrexate adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Thyroid Diseases chemically induced
- Abstract
Sixty-one children were examined for thyroid dysfunction as an adverse late effect after cessation of antileukemic treatment. The aim of the study was to contribute to clarifying which types of therapy can cause this endocrine disorder. Our treatment protocols do not include cranial irradiation as CNS prophylaxis, but we give relatively intensive intrathecal methotrexate treatment. The results indicate that this cytostatic regimen alone does not cause thyroid dysfunction as an adverse late effect.
- Published
- 1988
- Full Text
- View/download PDF
8. Structural chromosome aberrations in lymphocytes from children previously treated for Wilms' tumor or Hodgkin's disease.
- Author
-
Brøgger A, Kolmannskog S, Nicolaysen RB, Wesenberg F, and Nygaard R
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Chromosomes, Human drug effects, Chromosomes, Human radiation effects, Chromosomes, Human ultrastructure, Female, Humans, Infant, Male, Neoplasms, Multiple Primary, Risk, Sister Chromatid Exchange, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chromosome Aberrations, Hodgkin Disease therapy, Radiotherapy adverse effects, Wilms Tumor therapy
- Abstract
Nineteen children treated for Wilms' tumor (thirteen cases) or Hodgkin's disease (six cases) with cytostatic agents and/or radiotherapy were studied cytogenetically on lymphocytes cultivated from blood samples drawn after at least 1 year of complete remission after end of therapy. A reference group of children was matched for age, sex, and residence. The frequencies of sister chromatid exchange (5.4 versus 5.6 SCE/cell), and chromosome damage type gaps (6.6 versus 7.1%) and breaks (1.9 versus 1.9%) were not different in the two groups, but exchange type aberrations were more frequent in the patients (0.9 versus 0.06%). Fifty karyotypes were analyzed in all but two cases of Hodgkin's disease. The overall frequency of stable (3.1 versus 3.8%) and unstable (1.7 versus 1.4%) structural chromosome changes such as translocations, deletions, chromatid exchanges, and dicentrics were not different in the patient and the control groups. If the chromosome data reflect a general cancer risk, this risk cannot be considerably higher among the cancer-treated children.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.